A recent medical journal article presents an interesting case report about a 76-year-old woman with Beovu-related retinal vasculitis which was made worse by a later Lucentis treatment for her wet AMD. That patient’s doctors are the authors of “Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: A clinicopathologic case study”, which suggests this was a Beovu vision loss case due to delayed Beovu hypersensitivity.
In more detail, this woman was treated with three injections of Beovu resulting in retinal vasculitis and intraocular inflammation one week after the Beovu third injection. About one month later, her doctors administered a Lucentis treatment. Soon thereafter this patient developed severe vitritis with worsening occlusive retinal vasculitis.
When reading this Beovu case report it appears this woman’s doctors were not sure whether (1) Lucentis had a role in the retinal occlusive vasculitis, worsening intraocular inflammation, and severe vision loss she suffered soon after her Lucentis injection, or (2) this was a Beovu vision loss case due to delayed Beovu hypersensitivity.
In the Abstract for this Beovu case report, however, we find this statement at the “Conclusion and importance” part:
Treatment with [Beovu (brolucizumab)] can result in intraocular inflammation and retinal vasculitis likely due to a delayed hypersensitivity reaction to the drug, supported by cytopathologic analysis of a vitreous sample. We demonstrate a case where retreatment with an alternative anti-VEGF agent resulted in worsening vision and vasculitis.
Our law firm is investigating possible Beovu lawsuits for patients who have been diagnosed with Beovu-related retinal vasculitis and suffered vision loss or blindness. If we can be of assistance to you or someone else regarding a Beovu vision loss case, you can submit an online Beovu Case Evaluation Form or you can call us on our toll-free number: 800-426-9535.[View article at original source]